OLMA Stock — Olema Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$9.82

Market cap

$859.2M

Cash

$461.1M

Enterprise value

$398.1M

Balance sheet

Cash	$461.1M
Debt	$0.0M
Net cash	$461.1M
Enterprise value	$398.1M
Basic shares	87.5M shares
Fully diluted shares	120.0M shares
Fully diluted market cap	$1,178.7M
Cash per share	$5.27

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OLMA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 12, 2026 - Jan 23, 2027	Palazestrant	Phase 3	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer	—
Jul 11 - Aug 22	OP-3136	Phase 1	Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)	—
Feb 11 - Mar 24	Palazestrant	Phase 1	Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer	—
Jan 12 - Feb 23	Palazestrant	Phase 3	Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

palazestrant

Phase 3 · Active Modality: small molecule (oral; complete ER antagonist + selective ER degrader)

Aliases OP-1250

Target estrogen receptor (ER)

Partnerships Novartis: Dec 2024 CTCSA (ribociclib supply for OPERA-02; ~$275M repayment on Olema Compound Transaction/Change of Control to a third party); 2020-2023 agreements (ribociclib/alpelisib supply for Phase 1b/2). Pfizer: Sep 2025 non-exclusive CTCSA (atirmociclib supply for Phase 1b/2); 2020 agreement (palbociclib supply)

Indications

ER+/HER2- metastatic breast cancer, second/third-line (monotherapy) (Phase 3)
ER+/HER2- metastatic breast cancer, frontline (with ribociclib) (Phase 3)
ER+/HER2- metastatic breast cancer (Phase 1/2 combinations with CDK4/6, PI3Kα, mTOR, CDK4 inhibitors) (Phase 1)

Catalysts

— fall 2026
— 2027
— late 2027
— 2028

Status note Wholly-owned lead. OPERA-01 initiated Nov 2023; OPERA-02 initiated 2025. Worldwide development/commercialization rights owned.

OP-3136

Phase 1 · Active Modality: small molecule (oral; potent, selective KAT6 inhibitor)

Target KAT6

Partnerships Aurigene Oncology: 2022 collaboration (discovery). Bayer: May 2026 CTCSA (NUBEQA/darolutamide supply for Phase 1b/2 in mCRPC; Olema sponsors)

Indications

Breast and other solid tumor cancers (monotherapy; with fulvestrant; with palazestrant) (Phase 1)
Metastatic castration-resistant prostate cancer (with darolutamide) (Phase 1)

Catalysts

— Q4 2026

Status note IND cleared late 2024; Phase 1 enrolling.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Palazestrant
Lead indication	Breast Cancer
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06016738	Phase 3	Active, not recruiting	Sponsor	OLMA	—	Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer	—
NCT07085767	Phase 3	Recruiting	Sponsor	OLMA	NVS	Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer	—
NCT06784193	Phase 1	Recruiting	Sponsor	OLMA	—	Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)	—
NCT05508906	Phase 1	Active, not recruiting	Sponsor	OLMA	NVS, PFE	Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer	—
NCT05266105	Phase 1	Active, not recruiting	Sponsor	OLMA	PFE	Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Olema Pharmaceuticals, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	3,208,875	no change	1.73%	2026-08-14
Ikarian Capital	383,281	-215,000	0.78%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

OLMA — Olema Pharmaceuticals Inc.